The Price Tag
The financial commitment for popular weight loss medications like Mounjaro can be substantial, with monthly expenses ranging from approximately Rs 10,000
to Rs 22,000. While these costs represent the current market price for higher dosage forms, it's noted that lower doses might fall closer to Rs 12,000 or even Rs 10,000. Previously, some treatments were priced per injection, but the current pricing structure is typically monthly. Experts suggest that the cost is influenced by factors such as research and development investment by pharmaceutical companies and the patented nature of the drugs. However, as more pharmaceutical entities enter the market and create widespread awareness, there's an expectation that drug prices will eventually decrease over time. This price point makes weight management through medication a significant financial consideration for many individuals.
Who Qualifies?
Eligibility for prescription weight loss drugs is not universal and is primarily determined by specific medical conditions and body mass index (BMI). Doctors may prescribe these medications to individuals managing conditions like diabetes, pre-diabetes, or fatty liver disease, where weight loss can significantly improve health outcomes. A BMI of 27 or higher, coupled with existing health complications, can make someone a candidate. Furthermore, individuals with a BMI exceeding 30, even without immediate health issues, are generally considered suitable candidates. For those with severe obesity, indicated by a BMI of 40 or higher, these drugs can still be effective, but medical professionals might also suggest bariatric surgery as a primary or complementary treatment option due to the extent of weight management required.
Who Must Avoid?
It is critically important to understand who should not take these potent weight loss medications due to potential health risks and side effects. Individuals with a personal or family history of thyroid cancer are strongly advised against using these drugs. Similarly, a past or present medical history of pancreatitis is a significant contraindication. Those suffering from gastrointestinal issues should also refrain from these treatments. Additionally, individuals with active eye diseases, particularly those linked to diabetes, need to exercise caution. Before starting any weight loss drug, including those in the GLP-1 class like Ozempic and Mounjaro, consulting with a healthcare professional is paramount to assess potential impacts on physical, medical, emotional, and financial well-being.
